Refractory Adult Acute Myeloid Leukemia Clinical Trial
Official title:
A Phase 1 Study of Merestinib in Combination With LY2874455 in Relapsed or Refractory Acute Myeloid Leukemia
This research study is studying a combination of two targeted therapies as a possible
treatment for acute myeloid leukemia (AML) that has relapsed after initial treatment or did
not fully respond.
The name of the study interventions involved in this study are:
- Merestinib
- LY2874455
- This research study is a Phase I clinical trial, which tests the safety of an
investigational intervention and also tries to define the appropriate dose of the
investigational intervention to use for further studies. "Investigational" means that
the intervention is being studied.
- The FDA (the U.S. Food and Drug Administration) has not approved Merestinib or LY2874455
as a treatment for any disease.
- Merestinib is an oral drug known as a MET kinase inhibitor that is being developed as a
treatment for patients with advanced cancer. MET inhibitors work by stopping a signal
that a cell receives instructing it to grow.
- LY2874455 is an oral drug known as an FGFR inhibitor that is also being developed as a
treatment for patients with advanced cancer. FGFR inhibitors work by stopping a signal
that a cell receives instructing it to grow.
- In this research study, the investigators are investigating whether Merestinib and
LY2874455 is safe to give in combination in patients with AML. In previous laboratory
studies, it was found that leukemia cells responded to treatment with a MET inhibitor
and an FGFR inhibitor. However, it is not yet known whether this will also be the case
with LY2874455 and merestinib when given to participants.
;